Rare Disease Diagnostics Market Size, Share, and Industry Analysis by Test Type, Disease Type, Technology, Sample Type, End User, and Geography

Description

List of Tables

The global Rare Disease Diagnostics Market was valued at USD 1,696.9 million in 2025 and is estimated to reach USD 1,985.4 million in 2026. The market is projected to reach USD 9,516.1 million by 2036, registering a CAGR of 17.0% during the forecast period (2026-2036). This report provides a comprehensive assessment of the rapidly evolving rare disease diagnostics market by examining genetic testing, biochemical testing, imaging diagnostics, next-generation sequencing, newborn screening, clinical interpretation, genotype-directed therapies, competitive developments, and future growth opportunities across the rare disease and precision medicine landscape.

Rare disease diagnostics comprise the genetic, biochemical, imaging, and other diagnostic tests used to identify rare diseases, determine molecular causes, guide clinical management, and select patients for genotype-directed therapies. More than 7,000 rare diseases have been identified, collectively affecting an estimated 300 to 400 million people worldwide, and approximately 80% have a genetic origin. The market includes targeted gene panels, whole exome sequencing, whole genome sequencing, chromosomal microarray, Sanger sequencing, karyotyping, fluorescence in situ hybridization, PCR-based testing, enzyme assays, metabolite analysis, protein analysis, and imaging tests performed on blood, tissue, urine, saliva, amniotic fluid, and other sample types.

The growth of this market is mainly driven by increasing awareness and early diagnosis initiatives, growing government support and funding for rare disease research and diagnosis, advancements in genomic technologies, the rising recognition of rare genetic disorders, and the increasing adoption of next-generation sequencing in clinical settings. In addition, the expansion of newborn screening into genomic sequencing, the growing number of genotype-directed therapies that require a confirmed molecular diagnosis, and widening reimbursement for exome and genome testing are further supporting market growth. The declining cost of genome sequencing and the growing diagnostic yield of exome and genome testing are also encouraging a shift from sequential single-gene testing toward comprehensive genomic analysis.

This report delivers an in-depth analysis of the market by evaluating test types, disease categories, sequencing and molecular technologies, sample types, end users, clinical adoption trends, newborn screening programs, reimbursement policies, regulatory developments, pharmaceutical collaborations, and competitive strategies shaping industry growth. It assesses how genome-scale testing, rapid sequencing, artificial intelligence-assisted variant interpretation, curated genomic data, digital PCR, mass spectrometry, and integrated laboratory workflows are improving diagnostic yield, turnaround time, and access to rare disease diagnosis. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business, investment, product development, and market-entry decisions.

Market Dynamics

The increasing recognition of rare genetic disorders and the need to shorten the diagnostic odyssey remain among the primary drivers of the rare disease diagnostics market. Rare disease patients may see several physicians over multiple years before receiving an accurate diagnosis because symptoms are often nonspecific, conditions are individually uncommon, and access to clinical geneticists is limited. Greater awareness among patients, clinicians, and policymakers, together with early referral initiatives and rapid genome sequencing for critically ill infants, is increasing demand for diagnostic tests that can identify disease-causing variants more efficiently.

Advancements in genomic technologies are further accelerating market growth. The cost of sequencing a human genome has fallen from approximately USD 100 million in 2001 to under USD 1,000, making comprehensive genomic testing increasingly viable in routine clinical care. Exome and genome sequencing can achieve diagnostic yields of approximately 25% to 50% in selected patient populations, including children with unexplained developmental delay, multiple congenital anomalies, and complex neurological disorders. Next-generation sequencing is therefore gradually replacing sequential single-gene testing and expanding the role of genetic diagnosis in rare disease care.

Government support and policy initiatives are strengthening the market's clinical and commercial foundation. National rare disease strategies, genomic medicine programs, research alliances, and targeted funding are supporting diagnosis, screening, data generation, and access to specialist services. Regulatory pathways for individualized genetic therapies and therapies addressing very small patient populations are also linking therapeutic development directly to diagnostic demand, because a confirmed molecular diagnosis is required to identify eligible patients and monitor treatment.

The expansion of newborn screening into genomic sequencing represents a significant long-term opportunity. Established newborn screening programs use dried blood spots and biochemical assays to detect a limited number of conditions, while genomic sequencing can identify additional disorders that biochemical methods cannot detect. Large initiatives such as the Generation Study in England, genomic newborn screening programs in the U.S., and Australia's expanding screening investments are expected to create population-scale demand for sequencing, interpretation, reporting, and follow-up services.

Widening reimbursement for exome and genome testing is further supporting adoption. Medicaid coverage has expanded in several U.S. states, national genomic medicine programs are integrating sequencing into routine care, and healthcare systems are increasingly recognizing the clinical value of comprehensive testing for developmental disorders, rare disease, and critically ill infants. As more genotype-directed therapies become available, the economic value of obtaining a molecular diagnosis is expected to increase for patients, providers, payers, and pharmaceutical companies.

Despite favorable market conditions, the cost and complexity of rare disease testing remain important restraints. Exome and genome tests can cost several thousand dollars when sample processing, sequencing, bioinformatics, interpretation, and reporting are included. Patients without insurance coverage or with high-deductible plans may face substantial out-of-pocket costs. Repeat testing, reanalysis, functional studies, and additional family testing can further increase total diagnostic expenses, particularly when the initial result is non-diagnostic.

Limited access to genetic specialists, counselors, trained laboratory personnel, and bioinformatics expertise represents another market challenge. Primary care physicians in many developing regions receive limited training in medical genetics, while specialist services are concentrated in large urban hospitals. Laboratories must also manage thousands of variants, uncertain findings, phenotype matching, data privacy, and complex reporting requirements. Regulatory evidence requirements for low-volume rare disease assays can raise compliance costs and limit the availability of specialized tests.

The market nevertheless presents substantial opportunities through genome-scale interpretation and reanalysis, rapid genome sequencing for critical care, genomic newborn screening, AI-assisted variant prioritization, pharmaceutical-sponsored testing, curated genomic datasets, and expansion in Asia-Pacific and the Gulf states. Diagnostic laboratories and technology suppliers that combine low-cost testing, high diagnostic yield, rapid turnaround, interpretation expertise, and reimbursement support are expected to be well positioned to benefit from market growth.

Segment Analysis

The report provides detailed market analysis across test type, disease type, technology, sample type, end user, and geography, enabling stakeholders to identify high-growth opportunities and evolving trends in genomic medicine, rare disease diagnosis, newborn screening, precision therapeutics, laboratory services, and clinical interpretation.

Based on test type, the market is segmented into Genetic Testing, Biochemical Testing, Imaging Diagnostics, and Other Diagnostic Tests. Genetic Testing is further segmented into Next-Generation Sequencing, comprising targeted gene panels, whole exome sequencing, and whole genome sequencing, as well as chromosomal microarray, Sanger sequencing, karyotyping, fluorescence in situ hybridization, and PCR-based testing. Genetic Testing is expected to account for the largest share of 82.3% of the market in 2026 and is projected to register the highest CAGR of 18.2% during the forecast period, attributed to the genetic origin of approximately 80% of rare diseases and the replacement of sequential single-gene testing with comprehensive genomic approaches. Within next-generation sequencing, Targeted Gene Panels are expected to account for the largest share in 2026, while Whole Genome Sequencing is projected to register the highest CAGR of 27.4%, driven by first-tier use in intensive care and the gradual shift from exome to genome testing.

Based on disease type, the market is segmented into Neurological Disorders, Metabolic Disorders, Immunological Disorders, Hematological Disorders, Endocrine Disorders, Cardiovascular Rare Disorders, and Other Rare Diseases. Neurological Disorders are expected to account for the largest share of 33.1% of the rare disease diagnostics market in 2026 and are also projected to register the highest CAGR of 19.6% during the forecast period. The large share and strong growth of this segment are supported by the high genetic contribution to epilepsies, neurodevelopmental disorders, neuromuscular diseases, and developmental delay, as well as evidence that genomic testing can reduce costs associated with prolonged diagnostic journeys.

Based on technology, the market is segmented into Sequencing Technologies, comprising next-generation sequencing and Sanger sequencing, PCR-Based Technologies, comprising real-time PCR, digital PCR, and multiplex PCR, Mass Spectrometry, Microarray Technologies, Immunoassays, and Other Technologies. Sequencing Technologies are expected to account for the largest share of 60.8% of the market in 2026 and are projected to register the highest CAGR of 20.0% during the forecast period. The large share and rapid growth of this segment are driven by declining sequencing costs, increasing clinical adoption, a growing installed base of sequencing instruments, and the ability to analyze multiple genes and genomic regions in a single test. Within PCR-based technologies, Digital PCR is projected to register the highest CAGR of 21.1%.

Based on sample type, the market is segmented into Blood Samples, comprising whole blood, plasma, serum, and dried blood spots, as well as Tissue Samples, Urine Samples, Saliva Samples, Amniotic Fluid, and Other Sample Types. Blood Samples are expected to account for the largest share of 72.8% of the market in 2026 and are projected to register the highest CAGR of 18.0% during the forecast period. Blood is the standard sample for germline sequencing, biochemical analysis, and many clinical genetic tests, while dried blood spots are widely used in newborn screening. Saliva Samples are projected to register a CAGR of 17.2% as non-invasive sample collection expands in selected diagnostic and research workflows.

Based on end user, the market is segmented into Diagnostic Laboratories, comprising reference laboratories and clinical laboratories, Hospital Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Other End Users. Diagnostic Laboratories are expected to account for the largest share of 52.3% of the market in 2026 and are projected to register the highest CAGR of 18.6% during the forecast period. The segment's leadership is attributed to the concentration of exome and genome testing in specialized laboratories with clinical interpretation capabilities, as well as consolidation and capacity expansion among major testing providers. Hospital laboratories are also expected to gain importance as rapid sequencing, newborn screening, and clinical genomic medicine become more integrated into routine care.

Regional Analysis

The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider rare disease policy, reimbursement, newborn screening, genomic medicine programs, genetic testing infrastructure, specialist access, pharmaceutical research, healthcare expenditure, regulatory frameworks, and investments influencing market growth.

North America is expected to account for the largest share of 45.2% of the global Rare Disease Diagnostics Market in 2026. The region's leadership is supported by established reimbursement for exome and genome testing, the concentration of large genetic testing laboratories in the U.S., advanced clinical and reference laboratory infrastructure, extensive newborn screening, and strong pharmaceutical and biotechnology activity. Medicaid coverage for exome testing has expanded to additional lives in several states, while Canada's National Strategy for Drugs for Rare Diseases is providing substantial funding for rare disease diagnosis and treatment. The U.S. is expected to account for 90.1% of the North American market in 2026.

Europe is expected to account for the second-largest share of 23.4% of the rare disease diagnostics market in 2026. The region combines European-level coordination with national health systems that determine screening panels, reimbursement, and clinical pathways. The NHS Genomic Medicine Service in England, Plan France Medecine Genomique 2025, and the German genome sequencing model project are integrating genomic testing into routine care. Newborn screening coverage varies considerably across countries, while Germany is expected to account for the largest share of the regional market, at 19.6%. Switzerland is projected to register the highest CAGR among European countries, at 15.5%.

Asia-Pacific is projected to register the highest CAGR of 22.6% during the forecast period. Governments across the region are formalizing rare disease policies and expanding genomic medicine infrastructure. China has catalogued 207 rare diseases, Japan has designated more than 330 intractable diseases, South Korea supports genome sequencing for more than 1,300 eligible diseases, India operates a National Policy for Rare Diseases, and Australia is expanding newborn screening through Commonwealth funding. China is expected to account for the largest share of the regional market in 2026, at 46.8%, while Japan is projected to register the highest CAGR among countries covered in the report.

Latin America is expected to account for a share of 5.9% of the rare disease diagnostics market in 2026. The region has introduced legislation supporting broader newborn screening, although implementation varies across countries. Healthcare systems combine public insurance with private providers that perform much of the advanced genetic testing. Brazil is expected to account for the largest share of the regional market, at 59.3%, while Mexico is projected to register the highest CAGR, at 16.5%, driven by expanding diagnostic infrastructure and clinical research.

The Middle East & Africa is expected to account for a share of 3.8% of the rare disease diagnostics market in 2026. The region combines Gulf states investing in national genome programs with Sub-Saharan countries where genetic services remain limited. High rates of consanguineous marriage increase the prevalence of recessive disorders in the Gulf and support demand for population sequencing, premarital screening, newborn screening, and clinical genetic testing. Saudi Arabia is expected to account for the largest share of the regional market, at 33.2%, supported by its national genomic initiatives.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their sequencing platforms, diagnostic assays, biochemical tests, instruments, laboratory services, bioinformatics and interpretation capabilities, curated genomic databases, pharmaceutical partnerships, product launches, acquisitions, reimbursement strategies, geographic expansion initiatives, research and development investments, and recent business developments.

Competitive benchmarking enables stakeholders to evaluate companies based on diagnostic yield, turnaround time, test menu breadth, sequencing quality, clinical interpretation, phenotype matching, curated genomic data, reimbursement access, laboratory scale, report quality, service support, regulatory compliance, and pricing. The study also analyzes how market participants are responding to the shift toward genome-scale testing, genomic newborn screening, rapid critical-care sequencing, AI-assisted interpretation, genotype-directed therapies, and the increasing outsourcing of specialized diagnostics.

Consolidation has reshaped the laboratory tier, while product launches, acquisitions, partnerships with healthcare systems and pharmaceutical companies, and expansion of sequencing and interpretation capacity remain key competitive strategies. Key companies profiled in the report include Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Revvity, Inc., Labcorp Holdings Inc., GeneDx Holdings Corp., Tempus AI, Inc., Fulgent Genetics, Inc., Eurofins Scientific SE, Centogene GmbH, Blueprint Genetics, and Strand Life Sciences Pvt. Ltd.

How This Report Helps

Provides accurate market size estimates and long-term forecasts for the global rare disease diagnostics market.

Evaluates the impact of rare disease awareness, early diagnosis initiatives, genomic technologies, newborn screening, reimbursement, and genotype-directed therapies on market growth.

Identifies high-growth opportunities across test types, disease types, technologies, sample types, end users, and geographic regions.

Analyzes emerging trends in whole genome sequencing, rapid critical-care diagnosis, genomic newborn screening, AI-assisted variant interpretation, digital PCR, mass spectrometry, and curated genomic data.

Assesses the influence of test costs, diagnostic yield, reimbursement, specialist availability, regulatory requirements, data privacy, and interpretation capacity on adoption.

Benchmarks leading companies based on test menus, sequencing platforms, diagnostic services, clinical interpretation, laboratory scale, partnerships, reimbursement access, and competitive positioning.

Supports product development, laboratory expansion, investment planning, partnership evaluation, market entry, reimbursement strategy, and business growth decisions.

Delivers actionable market intelligence for diagnostic laboratories, hospitals, pharmaceutical and biotechnology companies, sequencing providers, academic researchers, clinicians, investors, distributors, and healthcare organizations.

Key Questions Answered

What is the current size of the global rare disease diagnostics market, and how is it expected to evolve through 2036?

Which technological, clinical, regulatory, reimbursement, and economic factors are driving market growth?

What are the major drivers, restraints, opportunities, and challenges influencing industry development?

Which test type, disease type, technology, sample type, end-user, and regional segments are expected to experience the strongest growth?

Why is Genetic Testing expected to account for the largest test-type share and register the fastest growth?

How will whole genome sequencing, rapid genome testing, and next-generation sequencing influence rare disease diagnosis?

Why are Neurological Disorders expected to dominate the disease-type segment and grow fastest?

How will genomic newborn screening, dried blood spots, and population-scale sequencing affect market development?

Which geographic markets present the most attractive business opportunities for rare disease diagnostics companies?

How are genotype-directed therapies, pharmaceutical-sponsored testing, AI-assisted interpretation, and curated genomic data changing the competitive landscape?

Who are the leading companies operating in the market, and what competitive strategies are they adopting?

What recent product launches, acquisitions, partnerships, reimbursement developments, regulatory initiatives, and technological innovations are shaping the market?

How can stakeholders leverage market intelligence from this report to support investment decisions, product development, laboratory planning, competitive benchmarking, and long-term business strategy?

Product Code: MRHC - 1041637

1. Introduction

1.1. Market Definition & Scope
1.2. Currency & Limitations

2. Research Methodology

2.1. Research Approach
2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
2.3. Market Assessment
- 2.3.1. Market Size Estimation
- 2.3.2. Bottom-Up Approach
- 2.3.3. Top-Down Approach
- 2.3.4. Growth Forecast
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Factors Affecting Market Growth
- 4.2.1. Drivers
  - 4.2.1.1. Increasing Awareness and Early Diagnosis Initiatives
  - 4.2.1.2. Growing Government Support and Funding for Rare Disease Research and Diagnosis
  - 4.2.1.3. Advancements in Genomic Technologies Enabling Better Rare Disease Identification
  - 4.2.1.4. Rising Prevalence of Rare Genetic Disorders Globally
  - 4.2.1.5. Increasing Adoption of Next-Generation Sequencing in Clinical Settings
- 4.2.2. Restraints
  - 4.2.2.1. High Cost of Rare Disease Diagnostic Tests Limiting Accessibility
  - 4.2.2.2. Limited Awareness Among Healthcare Professionals in Developing Regions
  - 4.2.2.3. Complex Regulatory Pathways for Rare Disease Diagnostics
- 4.2.3. Opportunities
  - 4.2.3.1. Expanding Newborn Screening Programs Worldwide Offer Significant Growth Opportunities
  - 4.2.3.2. Growing Focus on Precision Medicine and Personalized Treatment Approaches
  - 4.2.3.3. Increasing Strategic Collaborations Between Diagnostic Companies and Pharmaceutical Manufacturers
  - 4.2.3.4. Emerging Markets with Improving Healthcare Infrastructure
- 4.2.4. Challenges
  - 4.2.4.1. Long Diagnostic Odyssey for Rare Disease Patients
  - 4.2.4.2. Limited Reimbursement Coverage for Rare Disease Testing
4.3. Industry & Technology Trends
- 4.3.1. Integration of Genomic Sequencing Into Newborn Screening
- 4.3.2. Artificial Intelligence and Machine Learning in Rare Disease Diagnosis
4.4. Regulatory Analysis
- 4.4.1. International Organization for Standardization (ISO)
- 4.4.2. North America
- 4.4.3. Europe
- 4.4.4. Asia-Pacific
- 4.4.5. Latin America
- 4.4.6. Middle East & Africa
4.5. Value Chain Analysis
- 4.5.1. Raw Material Suppliers
- 4.5.2. Component Manufacturers
- 4.5.3. Diagnostic Manufacturers
- 4.5.4. Testing Laboratories and Service Providers
- 4.5.5. Healthcare Providers and End Users
- 4.5.6. Value Addition at Each Stage

5. Rare Disease Diagnostics Market Assessment, by Test Type

5.1. Overview
5.2. Genetic Testing
- 5.2.1. Next-Generation Sequencing (NGS)
  - 5.2.1.1. Whole Exome Sequencing (WES)
  - 5.2.1.2. Whole Genome Sequencing (WGS)
  - 5.2.1.3. Targeted Gene Panels
- 5.2.2. Sanger Sequencing
- 5.2.3. Chromosomal Microarray Analysis
- 5.2.4. Karyotyping
- 5.2.5. Fluorescence In Situ Hybridization (FISH)
- 5.2.6. PCR-Based Testing
5.3. Biochemical Testing
- 5.3.1. Enzyme Assays
- 5.3.2. Metabolite Analysis
- 5.3.3. Protein Analysis
5.4. Imaging Diagnostics
5.5. Other Diagnostic Tests

6. Rare Disease Diagnostics Market Assessment, by Disease Type

6.1. Overview
6.2. Neurological Disorders
6.3. Metabolic Disorders
6.4. Hematological Disorders
6.5. Immunological Disorders
6.6. Endocrine Disorders
6.7. Cardiovascular Disorders
6.8. Other Rare Diseases

7. Rare Disease Diagnostics Market Assessment, by Technology

7.1. Overview
7.2. Sequencing Technologies
- 7.2.1. Next-Generation Sequencing
- 7.2.2. Sanger Sequencing
7.3. PCR-Based Technologies
- 7.3.1. Real-Time PCR
- 7.3.2. Digital PCR
- 7.3.3. Multiplex PCR
7.4. Microarray Technologies
7.5. Mass Spectrometry
7.6. Immunoassays
7.7. Other Technologies

8. Rare Disease Diagnostics Market Assessment, by Sample Type

8.1. Overview
8.2. Blood Samples
- 8.2.1. Whole Blood
- 8.2.2. Plasma
- 8.2.3. Serum
- 8.2.4. Dried Blood Spots
8.3. Urine Samples
8.4. Saliva Samples
8.5. Tissue Samples
8.6. Amniotic Fluid
8.7. Other Sample Types

9. Rare Disease Diagnostics Market Assessment, by End User

9.1. Overview
9.2. Diagnostic Laboratories
- 9.2.1. Reference Laboratories
- 9.2.2. Clinical Laboratories
9.3. Hospital Laboratories
9.4. Academic & Research Institutes
9.5. Pharmaceutical & Biotechnology Companies
9.6. Other End Users

10. Rare Disease Diagnostics Market Assessment, by Geography

10.1. Overview
10.2. North America
- 10.2.1. U.S.
- 10.2.2. Canada
10.3. Europe
- 10.3.1. Germany
- 10.3.2. France
- 10.3.3. U.K.
- 10.3.4. Italy
- 10.3.5. Spain
- 10.3.6. Switzerland
- 10.3.7. Belgium
- 10.3.8. Rest of Europe
10.4. Asia-Pacific
- 10.4.1. China
- 10.4.2. Japan
- 10.4.3. India
- 10.4.4. Australia
- 10.4.5. South Korea
- 10.4.6. Rest of Asia-Pacific
10.5. Latin America
- 10.5.1. Brazil
- 10.5.2. Mexico
- 10.5.3. Rest of Latin America
10.6. Middle East & Africa
- 10.6.1. Saudi Arabia
- 10.6.2. UAE
- 10.6.3. South Africa
- 10.6.4. Rest of Middle East & Africa

11. Competitive Landscape

11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
- 11.4.1. Industry Leaders
- 11.4.2. Market Differentiators
- 11.4.3. Vanguards
- 11.4.4. Emerging Companies
11.5. Market Share/Position Analysis

12. Company Profiles

12.1. Illumina, Inc. (U.S.)
- 12.1.1. Company Overview
- 12.1.2. Financial Overview
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Developments
12.2. Thermo Fisher Scientific Inc. (U.S.)
- 12.2.1. Company Overview
- 12.2.2. Financial Overview
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Developments
12.3. Agilent Technologies, Inc. (U.S.)
- 12.3.1. Company Overview
- 12.3.2. Financial Overview
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Developments
12.4. QIAGEN N.V. (Netherlands)
- 12.4.1. Company Overview
- 12.4.2. Financial Overview
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Developments
12.5. Bio-Rad Laboratories, Inc. (U.S.)
- 12.5.1. Company Overview
- 12.5.2. Financial Overview
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Developments
12.6. F. Hoffmann-La Roche Ltd (Switzerland)
- 12.6.1. Company Overview
- 12.6.2. Financial Overview
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Developments
12.7. Revvity, Inc. (U.S.)
- 12.7.1. Company Overview
- 12.7.2. Financial Overview
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Developments
12.8. Labcorp Holdings Inc. (U.S.)
- 12.8.1. Company Overview
- 12.8.2. Financial Overview
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Developments
12.9. GeneDx Holdings Corp. (U.S.)
- 12.9.1. Company Overview
- 12.9.2. Financial Overview
- 12.9.3. Product Portfolio
- 12.9.4. Strategic Developments
12.10. Tempus AI, Inc. (U.S.)
- 12.10.1. Company Overview
- 12.10.2. Financial Overview
- 12.10.3. Product Portfolio
- 12.10.4. Strategic Developments
12.11. Fulgent Genetics, Inc. (U.S.)
- 12.11.1. Company Overview
- 12.11.2. Financial Overview
- 12.11.3. Product Portfolio
- 12.11.4. Strategic Developments
12.12. Eurofins Scientific SE (Luxembourg)
- 12.12.1. Company Overview
- 12.12.2. Financial Overview
- 12.12.3. Product Portfolio
- 12.12.4. Strategic Developments
12.13. Centogene GmbH (Germany)
- 12.13.1. Company Overview
- 12.13.2. Financial Overview
- 12.13.3. Product Portfolio
- 12.13.4. Strategic Developments
12.14. Blueprint Genetics (Finland)
- 12.14.1. Company Overview
- 12.14.2. Financial Overview
- 12.14.3. Product Portfolio
- 12.14.4. Strategic Developments
12.15. Strand Life Sciences Pvt. Ltd. (India)
- 12.15.1. Company Overview
- 12.15.2. Financial Overview
- 12.15.3. Product Portfolio
- 12.15.4. Strategic Developments

13. Appendix

13.1. Available Customization
13.2. Related Reports

Product Code: MRHC - 1041637

LIST OF TABLES

List of Tables

Table 1 Currency Conversion Rates, 2022-2025
Table 2 Global Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 3 Global Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 4 Global Rare Disease Diagnostics Market for Genetic Testing, by Region/Country, 2024-2036 (USD Million)
Table 5 Global Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 6 Global Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Region/Country, 2024-2036 (USD Million)
Table 7 Global Rare Disease Diagnostics Market for Whole Exome Sequencing (WES), by Region/Country, 2024-2036 (USD Million)
Table 8 Global Rare Disease Diagnostics Market for Whole Genome Sequencing (WGS), by Region/Country, 2024-2036 (USD Million)
Table 9 Global Rare Disease Diagnostics Market for Targeted Gene Panels, by Region/Country, 2024-2036 (USD Million)
Table 10 Global Rare Disease Diagnostics Market for Sanger Sequencing, by Region/Country, 2024-2036 (USD Million)
Table 11 Global Rare Disease Diagnostics Market for Chromosomal Microarray Analysis (CMA), by Region/Country, 2024-2036 (USD Million)
Table 12 Global Rare Disease Diagnostics Market for Karyotyping by Region/Country, 2024-2036 (USD Million)
Table 13 Global Rare Disease Diagnostics Market for Fluorescence In Situ Hybridization (FISH), by Region/Country, 2024-2036 (USD Million)
Table 14 Global Rare Disease Diagnostics Market for PCR-Based Testing, by Region/Country, 2024-2036 (USD Million)
Table 15 Global Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 16 Global Rare Disease Diagnostics Market for Biochemical Testing, by Region/Country, 2024-2036 (USD Million)
Table 17 Global Rare Disease Diagnostics Market for Enzyme Assays, by Region/Country, 2024-2036 (USD Million)
Table 18 Global Rare Disease Diagnostics Market for Metabolite Analysis, by Region/Country, 2024-2036 (USD Million)
Table 19 Global Rare Disease Diagnostics Market for Protein Analysis, by Region/Country, 2024-2036 (USD Million)
Table 20 Global Rare Disease Diagnostics Market for Imaging Diagnostics, by Region/Country, 2024-2036 (USD Million)
Table 21 Global Rare Disease Diagnostics Market for Other Diagnostic Tests, by Region/Country, 2024-2036 (USD Million)
Table 22 Global Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 23 Global Rare Disease Diagnostics Market for Neurological Disorders, by Region/Country, 2024-2036 (USD Million)
Table 24 Global Rare Disease Diagnostics Market for Metabolic Disorders, by Region/Country, 2024-2036 (USD Million)
Table 25 Global Rare Disease Diagnostics Market for Hematological Disorders, by Region/Country, 2024-2036 (USD Million)
Table 26 Global Rare Disease Diagnostics Market for Immunological Disorders, by Region/Country, 2024-2036 (USD Million)
Table 27 Global Rare Disease Diagnostics Market for Endocrine Disorders, by Region/Country, 2024-2036 (USD Million)
Table 28 Global Rare Disease Diagnostics Market for Cardiovascular Rare Disorders, by Region/Country, 2024-2036 (USD Million)
Table 29 Global Rare Disease Diagnostics Market for Other Rare Diseases, by Region/Country, 2024-2036 (USD Million)
Table 30 Global Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 31 Global Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 32 Global Rare Disease Diagnostics Market for Sequencing Technologies, by Region/Country, 2024-2036 (USD Million)
Table 33 Global Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Region/Country, 2024-2036 (USD Million)
Table 34 Global Rare Disease Diagnostics Market for Sanger Sequencing, by Region/Country, 2024-2036 (USD Million)
Table 35 Global Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 36 Global Rare Disease Diagnostics Market for PCR-Based Technologies, by Region/Country, 2024-2036 (USD Million)
Table 37 Global Rare Disease Diagnostics Market for Real-Time PCR (qRT-PCR), by Region/Country, 2024-2036 (USD Million)
Table 38 Global Rare Disease Diagnostics Market for Digital PCR (dPCR), by Region/Country, 2024-2036 (USD Million)
Table 39 Global Rare Disease Diagnostics Market for Multiplex PCR, by Region/Country, 2024-2036 (USD Million)
Table 40 Global Rare Disease Diagnostics Market for Microarray Technologies, by Region/Country, 2024-2036 (USD Million)
Table 41 Global Rare Disease Diagnostics Market for Mass Spectrometry, by Region/Country, 2024-2036 (USD Million)
Table 42 Global Rare Disease Diagnostics Market for Immunoassays, by Region/Country, 2024-2036 (USD Million)
Table 43 Global Rare Disease Diagnostics Market for Other Technologies, by Region/Country, 2024-2036 (USD Million)
Table 44 Global Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 45 Global Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 46 Global Rare Disease Diagnostics Market for Blood Samples, by Region/Country, 2024-2036 (USD Million)
Table 47 Global Rare Disease Diagnostics Market for Whole Blood, by Region/Country, 2024-2036 (USD Million)
Table 48 Global Rare Disease Diagnostics Market for Plasma, by Region/Country, 2024-2036 (USD Million)
Table 49 Global Rare Disease Diagnostics Market for Serum, by Region/Country, 2024-2036 (USD Million)
Table 50 Global Rare Disease Diagnostics Market for Dried Blood Spots (DBS), by Region/Country, 2024-2036 (USD Million)
Table 51 Global Rare Disease Diagnostics Market for Urine Samples, by Region/Country, 2024-2036 (USD Million)
Table 52 Global Rare Disease Diagnostics Market for Saliva Samples, by Region/Country, 2024-2036 (USD Million)
Table 53 Global Rare Disease Diagnostics Market for Tissue Samples, by Region/Country, 2024-2036 (USD Million)
Table 54 Global Rare Disease Diagnostics Market for Amniotic Fluid, by Region/Country, 2024-2036 (USD Million)
Table 55 Global Rare Disease Diagnostics Market for Other Sample Types, by Region/Country, 2024-2036 (USD Million)
Table 56 Global Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 57 Global Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 58 Global Rare Disease Diagnostics Market for Diagnostic Laboratories, by Region/Country, 2024-2036 (USD Million)
Table 59 Global Rare Disease Diagnostics Market for Reference Laboratories, by Region/Country, 2024-2036 (USD Million)
Table 60 Global Rare Disease Diagnostics Market for Clinical Laboratories, by Region/Country, 2024-2036 (USD Million)
Table 61 Global Rare Disease Diagnostics Market for Hospital Laboratories, by Region/Country, 2024-2036 (USD Million)
Table 62 Global Rare Disease Diagnostics Market for Academic & Research Institutes, by Region/Country, 2024-2036 (USD Million)
Table 63 Global Rare Disease Diagnostics Market for Pharmaceutical & Biotechnology Companies, by Region/Country, 2024-2036 (USD Million)
Table 64 Global Rare Disease Diagnostics Market for Other End User, by Region/Country, 2024-2036 (USD Million)
Table 65 North America: Rare Disease Diagnostics Market, by Country, 2024-2036 (USD Million)
Table 66 North America: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 67 North America: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 68 North America: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 69 North America: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 70 North America: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 71 North America: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 72 North America: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 73 North America: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 74 North America: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 75 North America: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 76 North America: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 77 North America: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 78 U.S.: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 79 U.S.: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 80 U.S.: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 81 U.S.: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 82 U.S.: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 83 U.S.: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 84 U.S.: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 85 U.S.: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 86 U.S.: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 87 U.S.: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 88 U.S.: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 89 U.S.: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 90 Canada: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 91 Canada: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 92 Canada: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 93 Canada: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 94 Canada: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 95 Canada: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 96 Canada: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 97 Canada: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 98 Canada: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 99 Canada: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 100 Canada: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 101 Canada: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 102 Europe: Rare Disease Diagnostics Market, by Country, 2024-2036 (USD Million)
Table 103 Europe: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 104 Europe: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 105 Europe: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 106 Europe: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 107 Europe: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 108 Europe: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 109 Europe: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 110 Europe: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 111 Europe: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 112 Europe: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 113 Europe: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 114 Europe: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 115 Germany: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 116 Germany: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 117 Germany: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 118 Germany: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 119 Germany: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 120 Germany: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 121 Germany: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 122 Germany: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 123 Germany: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 124 Germany: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 125 Germany: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 126 Germany: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 127 France: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 128 France: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 129 France: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 130 France: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 131 France: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 132 France: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 133 France: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 134 France: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 135 France: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 136 France: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 137 France: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 138 France: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 139 U.K.: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 140 U.K.: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 141 U.K.: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 142 U.K.: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 143 U.K.: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 144 U.K.: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 145 U.K.: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 146 U.K.: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 147 U.K.: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 148 U.K.: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 149 U.K.: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 150 U.K.: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 151 Italy: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 152 Italy: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 153 Italy: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 154 Italy: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 155 Italy: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 156 Italy: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 157 Italy: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 158 Italy: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 159 Italy: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 160 Italy: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 161 Italy: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 162 Italy: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 163 Spain: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 164 Spain: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 165 Spain: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 166 Spain: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 167 Spain: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 168 Spain: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 169 Spain: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 170 Spain: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 171 Spain: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 172 Spain: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 173 Spain: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 174 Spain: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 175 Switzerland: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 176 Switzerland: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 177 Switzerland: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 178 Switzerland: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 179 Switzerland: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 180 Switzerland: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 181 Switzerland: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 182 Switzerland: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 183 Switzerland: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 184 Switzerland: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 185 Switzerland: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 186 Switzerland: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 187 Belgium: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 188 Belgium: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 189 Belgium: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 190 Belgium: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 191 Belgium: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 192 Belgium: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 193 Belgium: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 194 Belgium: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 195 Belgium: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 196 Belgium: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 197 Belgium: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 198 Belgium: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 199 Rest of Europe: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 200 Rest of Europe: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 201 Rest of Europe: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 202 Rest of Europe: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 203 Rest of Europe: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 204 Rest of Europe: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 205 Rest of Europe: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 206 Rest of Europe: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 207 Rest of Europe: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 208 Rest of Europe: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 209 Rest of Europe: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 210 Rest of Europe: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 211 Asia-Pacific: Rare Disease Diagnostics Market, by Country, 2024-2036 (USD Million)
Table 212 Asia-Pacific: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 213 Asia-Pacific: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 214 Asia-Pacific: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 215 Asia-Pacific: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 216 Asia-Pacific: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 217 Asia-Pacific: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 218 Asia-Pacific: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 219 Asia-Pacific: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 220 Asia-Pacific: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 221 Asia-Pacific: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 222 Asia-Pacific: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 223 Asia-Pacific: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 224 China: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 225 China: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 226 China: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 227 China: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 228 China: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 229 China: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 230 China: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 231 China: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 232 China: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 233 China: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 234 China: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 235 China: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 236 Japan: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 237 Japan: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 238 Japan: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 239 Japan: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 240 Japan: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 241 Japan: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 242 Japan: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 243 Japan: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 244 Japan: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 245 Japan: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 246 Japan: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 247 Japan: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 248 India: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 249 India: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 250 India: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 251 India: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 252 India: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 253 India: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 254 India: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 255 India: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 256 India: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 257 India: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 258 India: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 259 India: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 260 Australia: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 261 Australia: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 262 Australia: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 263 Australia: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 264 Australia: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 265 Australia: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 266 Australia: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 267 Australia: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 268 Australia: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 269 Australia: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 270 Australia: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 271 Australia: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 272 South Korea: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 273 South Korea: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 274 South Korea: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 275 South Korea: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 276 South Korea: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 277 South Korea: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 278 South Korea: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 279 South Korea: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 280 South Korea: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 281 South Korea: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 282 South Korea: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 283 South Korea: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 284 Rest of Asia-Pacific: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 285 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 286 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 287 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 288 Rest of Asia-Pacific: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 289 Rest of Asia-Pacific: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 290 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 291 Rest of Asia-Pacific: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 292 Rest of Asia-Pacific: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 293 Rest of Asia-Pacific: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 294 Rest of Asia-Pacific: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 295 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 296 Latin America: Rare Disease Diagnostics Market, by Country, 2024-2036 (USD Million)
Table 297 Latin America: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 298 Latin America: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 299 Latin America: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 300 Latin America: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 301 Latin America: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 302 Latin America: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 303 Latin America: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 304 Latin America: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 305 Latin America: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 306 Latin America: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 307 Latin America: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 308 Latin America: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 309 Brazil: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 310 Brazil: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 311 Brazil: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 312 Brazil: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 313 Brazil: Rare Disea

Table 314 Brazil: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 315 Brazil: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 316 Brazil: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 317 Brazil: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 318 Brazil: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 319 Brazil: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 320 Brazil: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 321 Mexico: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 322 Mexico: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 323 Mexico: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 324 Mexico: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 325 Mexico: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 326 Mexico: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 327 Mexico: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 328 Mexico: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 329 Mexico: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 330 Mexico: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 331 Mexico: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 332 Mexico: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 333 Rest of Latin America: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 334 Rest of Latin America: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 335 Rest of Latin America: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 336 Rest of Latin America: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 337 Rest of Latin America: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 338 Rest of Latin America: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 339 Rest of Latin America: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 340 Rest of Latin America: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 341 Rest of Latin America: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 342 Rest of Latin America: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 343 Rest of Latin America: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 344 Rest of Latin America: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 345 Middle East & Africa: Rare Disease Diagnostics Market, by Country, 2024-2036 (USD Million)
Table 346 Middle East & Africa: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 347 Middle East & Africa: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 348 Middle East & Africa: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 349 Middle East & Africa: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 350 Middle East & Africa: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 351 Middle East & Africa: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 352 Middle East & Africa: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 353 Middle East & Africa: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 354 Middle East & Africa: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 355 Middle East & Africa: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 356 Middle East & Africa: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 357 Middle East & Africa: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 358 Saudi Arabia: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 359 Saudi Arabia: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 360 Saudi Arabia: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 361 Saudi Arabia: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 362 Saudi Arabia: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 363 Saudi Arabia: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 364 Saudi Arabia: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 365 Saudi Arabia: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 366 Saudi Arabia: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 367 Saudi Arabia: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 368 Saudi Arabia: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 369 Saudi Arabia: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 370 UAE: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 371 UAE: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 372 UAE: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 373 UAE: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 374 UAE: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 375 UAE: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 376 UAE: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 377 UAE: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 378 UAE: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 379 UAE: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 380 UAE: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 381 UAE: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 382 South Africa: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 383 South Africa: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 384 South Africa: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 385 South Africa: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 386 South Africa: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 387 South Africa: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 388 South Africa: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 389 South Africa: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 390 South Africa: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 391 South Africa: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 392 South Africa: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 393 South Africa: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 394 Rest of Middle East & Africa: Rare Disease Diagnostics Market, by Type, 2024-2036 (USD Million)
Table 395 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Genetic Testing, by Type, 2024-2036 (USD Million)
Table 396 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2024-2036 (USD Million)
Table 397 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2024-2036 (USD Million)
Table 398 Rest of Middle East & Africa: Rare Disease Diagnostics Market, by Disease Type, 2024-2036 (USD Million)
Table 399 Rest of Middle East & Africa: Rare Disease Diagnostics Market, by Technology, 2024-2036 (USD Million)
Table 400 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2024-2036 (USD Million)
Table 401 Rest of Middle East & Africa: Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2024-2036 (USD Million)
Table 402 Rest of Middle East & Africa: Rare Disease Diagnostics Market, by Sample Type, 2024-2036 (USD Million)
Table 403 Rest of Middle East & Africa: Rare Disease Diagnostics Market, by Blood Sample Type, 2024-2036 (USD Million)
Table 404 Rest of Middle East & Africa: Rare Disease Diagnostics Market, by End User, 2024-2036 (USD Million)
Table 405 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2024-2036 (USD Million)
Table 406 Rare Disease Diagnostics Market: Competitive Benchmarking, by Offering
Table 407 Rare Disease Diagnostics Market: Competitive Benchmarking, by Geographic Presence
Table 408 Illumina, Inc.: Product Portfolio
Table 409 Illumina, Inc.: Strategic Developments, 2025-2026
Table 410 Thermo Fisher Scientific Inc.: Product Portfolio
Table 411 Thermo Fisher Scientific Inc.: Strategic Developments, 2025-2026
Table 412 Agilent Technologies, Inc.: Product Portfolio
Table 413 Agilent Technologies, Inc.: Strategic Developments, 2025-2026
Table 414 QIAGEN N.V.: Product Portfolio
Table 415 QIAGEN N.V.: Strategic Developments, 2025-2026
Table 416 Bio-Rad Laboratories, Inc.: Product Portfolio
Table 417 Bio-Rad Laboratories, Inc.: Strategic Developments, 2025-2026
Table 418 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 419 F. Hoffmann-La Roche Ltd: Strategic Developments, 2025-2026
Table 420 Revvity, Inc.: Product Portfolio
Table 421 Revvity, Inc.: Strategic Developments, 2025-2026
Table 422 Labcorp Holdings Inc.: Product Portfolio
Table 423 Labcorp Holdings Inc.: Strategic Developments, 2025-2026
Table 424 GeneDx Holdings Corp.: Product Portfolio
Table 425 GeneDx Holdings Corp.: Strategic Developments, 2025-2026
Table 426 Tempus AI, Inc.: Product Portfolio
Table 427 Tempus AI, Inc.: Strategic Developments, 2025-2026
Table 428 Fulgent Genetics, Inc.: Product Portfolio
Table 429 Fulgent Genetics, Inc.: Strategic Developments, 2025-2026
Table 430 Eurofins Scientific SE: Product Portfolio
Table 431 Eurofins Scientific SE: Strategic Developments, 2025-2026
Table 432 Centogene GmbH: Product Portfolio
Table 433 Centogene GmbH: Strategic Developments, 2025-2026
Table 434 Blueprint Genetics: Product Portfolio
Table 435 Strand Life Sciences Pvt. Ltd.: Product Portfolio
Table 436 Strand Life Sciences Pvt. Ltd.: Strategic Developments, 2025-2026

LIST OF FIGURES

List of Figures

Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Rare Disease Diagnostics Market Size, by Test Type, 2024-2036 (USD Million)
Figure 8 Rare Disease Diagnostics Market: Key Findings
Figure 9 Global Rare Disease Diagnostics Market, by Test Type, 2026 vs. 2036 (USD Million)
Figure 10 Global Rare Disease Diagnostics Market, by Disease, 2026 vs. 2036 (USD Million)
Figure 11 Global Rare Disease Diagnostics Market, by Technology, 2026 vs. 2036 (USD Million)
Figure 12 Global Rare Disease Diagnostics Market, by Sample Type, 2026 vs. 2036 (USD Million)
Figure 13 Global Rare Disease Diagnostics Market, by End User, 2026 vs. 2036 (USD Million)
Figure 14 Rare Disease Diagnostics Market, by Geography
Figure 15 Test Volume Versus Test Value: Evidence from Leading Providers, 2025-2026
Figure 16 Factors Affecting Market Growth
Figure 17 Economic and Clinical Evidence for Early Genomic Diagnosis
Figure 18 Rare Disease Regulatory and Funding Milestones, 2024-2026
Figure 19 Diagnostic Yield of National Genome Sequencing Programmes (%)
Figure 20 Diagnostic Yield, by Testing Approach (%)
Figure 21 Early Check Genomic Newborn Screening: First 1,979 Newborns
Figure 22 Clinical Exome and Genome Test Volumes, Selected Providers, 2025
Figure 23 Growth in Volume Versus Revenue and Margin, 2025-2026
Figure 24 Price of a Basic Genomic Test in India (Inr)
Figure 25 EU IVDR Transition Deadlines and U.S. Laboratory-Developed Test Ruling
Figure 26 Newborn Screening Panel Size, Selected Countries (Number of Conditions)
Figure 27 Genomic Data Services: Tempus Data and Applications Revenue (USD Million)
Figure 28 The Diagnostic Odyssey and the Effect of First-Tier Genome Sequencing
Figure 29 Reimbursement Milestones for Genomic Testing, 2025-2026
Figure 30 Genomic Newborn Screening Programmes, by Cohort Size
Figure 31 Scale of AI-Enabled Variant Interpretation Platforms
Figure 32 Value Chain Analysis
Figure 33 Global Rare Disease Diagnostics Market, by Type, 2026 vs. 2036 (USD Million)
Figure 34 Global Rare Disease Diagnostics Market for Genetic Testing, by Type, 2026 vs. 2036 (USD Million)
Figure 35 Next-Generation Sequencing Approaches Compared, 2026-2036
Figure 36 Global Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), by Type, 2026 vs. 2036 (USD Million)
Figure 37 Rapid Genome Sequencing in Intensive Care: Clinical and Economic Evidence
Figure 38 Cytogenetic Testing Methods Compared
Figure 39 SMA Newborn Screening with a Digital PCR Second Tier: Taiwan Program
Figure 40 U.S. Recommended Uniform Screening Panel: Conditions Added, 2010-2025
Figure 41 Global Rare Disease Diagnostics Market for Biochemical Testing, by Type, 2026 vs. 2036 (USD Million)
Figure 42 Global Rare Disease Diagnostics Market, by Disease Type, 2026 vs. 2036 (USD Million)
Figure 43 Metabolic Screening Coverage: Selected National Programs
Figure 44 Sickle Cell Disease: Burden, Screening and Genotype-Directed Therapy
Figure 45 Severe Combined Immunodeficiency: From Newborn Screen to Treatment
Figure 46 Genetic Testing in Inherited Cardiomyopathies: Yield and Follow-Through
Figure 47 Global Rare Disease Diagnostics Market, by Technology, 2026 vs. 2036 (USD Million)
Figure 48 Sequencing Platform Landscape, 2025-2026
Figure 49 Global Rare Disease Diagnostics Market for Sequencing Technologies, by Type, 2026 vs. 2036 (USD Million)
Figure 50 Global Rare Disease Diagnostics Market for PCR-Based Technologies, by Type, 2026 vs. 2036 (USD Million)
Figure 51 Digital PCR in Rare Disease Testing: Evidence and Supplier Investment
Figure 52 Global Rare Disease Diagnostics Market, by Sample Type, 2026 vs. 2036 (USD Million)
Figure 53 Global Rare Disease Diagnostics Market, by Blood Sample Type, 2026 vs. 2036 (USD Million)
Figure 54 Diagnostic Yield of Prenatal Exome Sequencing in Fetal Structural Anomalies (%)
Figure 55 Global Rare Disease Diagnostics Market, by End User, 2026 vs. 2036 (USD Million)
Figure 56 Consolidation of the Rare Disease Testing Laboratory Tier, 2024-2026
Figure 57 Global Rare Disease Diagnostics Market for Diagnostic Laboratories, by Type, 2026 vs. 2036 (USD Million)
Figure 58 Scale of Leading Rare Disease Reference Laboratories
Figure 59 Hospital-Based Genomic Testing: Reach and Public Programs
Figure 60 Why Drug Developers Fund Rare Disease Diagnosis
Figure 61 Global Rare Disease Diagnostics Market, by Region, 2026 vs. 2036 (USD Million)
Figure 62 North America: Policy and Coverage Drivers, 2025-2026
Figure 63 North America: Rare Disease Diagnostics Market Snapshot
Figure 64 National Genome Sequencing Programs in Europe
Figure 65 Europe: Rare Disease Diagnostics Market Snapshot
Figure 66 Italy: Development of Extended Newborn Screening
Figure 67 State-Funded Rare Disease Diagnosis in Asia-Pacific
Figure 68 Asia-Pacific: Rare Disease Diagnostics Market Snapshot
Figure 69 Japan: Rare Disease Policy Milestones
Figure 70 Mackenzie's Mission: Reproductive Carrier Screening in Australia
Figure 71 Newborn Screening in Latin America: Legislation and Implementation
Figure 72 Latin America: Rare Disease Diagnostics Market Snapshot
Figure 73 Population Genome Programs in the Gulf
Figure 74 Middle East and Africa: Rare Disease Diagnostics Market Snapshot
Figure 75 South Africa: Medical Aid Coverage, by Province, 2024 (%)
Figure 76 Rare Disease Diagnostics Market: Key Growth Strategies Adopted by Leading Players, January 2025-SEPTEMBER 2026
Figure 77 Rare Disease Diagnostics Market: Competitive Dashboard
Figure 78 Rare Disease Diagnostics Market: Market Position Analysis, 2025
Figure 79 Illumina, Inc.: Financial Overview
Figure 80 Thermo Fisher Scientific Inc.: Financial Overview
Figure 81 Agilent Technologies, Inc.: Financial Overview
Figure 82 QIAGEN N.V.: Financial Overview
Figure 83 Bio-Rad Laboratories, Inc.: Financial Overview
Figure 84 F. Hoffmann-La Roche Ltd: Financial Overview
Figure 85 Revvity, Inc.: Financial Overview
Figure 86 Labcorp Holdings Inc.: Financial Overview
Figure 87 GeneDx Holdings Corp.: Financial Overview
Figure 88 Tempus AI, Inc.: Financial Overview
Figure 89 Fulgent Genetics, Inc.: Financial Overview
Figure 90 Eurofins Scientific SE: Financial Overview

Rare Disease Diagnostics Market Size, Share, and Industry Analysis by Test Type, Disease Type, Technology, Sample Type, End User, and Geography - Global Forecast to 2036

Description

Table of Contents

List of Tables

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

5. Rare Disease Diagnostics Market Assessment, by Test Type

6. Rare Disease Diagnostics Market Assessment, by Disease Type

7. Rare Disease Diagnostics Market Assessment, by Technology

8. Rare Disease Diagnostics Market Assessment, by Sample Type

9. Rare Disease Diagnostics Market Assessment, by End User

10. Rare Disease Diagnostics Market Assessment, by Geography

11. Competitive Landscape

12. Company Profiles

13. Appendix

LIST OF TABLES

List of Tables

LIST OF FIGURES

List of Figures